Entera Bio Ltd. Amends Filing on Shareholder Votes and Warrants
Ticker: ENTX · Form: 8-K/A · Filed: Dec 20, 2024 · CIK: 1638097
| Field | Detail |
|---|---|
| Company | Entera Bio LTD. (ENTX) |
| Form Type | 8-K/A |
| Filed Date | Dec 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, warrants, shareholder-vote
Related Tickers: ENTX
TL;DR
Entera Bio Ltd. filed an 8-K/A amendment detailing warrants exercisable at $5.85/share.
AI Summary
Entera Bio Ltd. filed an amendment (8-K/A) on December 20, 2024, related to events on July 31, 2024. The filing concerns matters submitted to a vote of security holders. Specifically, it details warrants exercisable for half an Ordinary Share at an exercise price of $5.85 per share.
Why It Matters
This amendment clarifies details regarding outstanding warrants and their terms, which could impact the potential dilution and future share structure for investors.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not introduce new material risks but clarifies existing information.
Key Numbers
- $5.85 — Warrant Exercise Price (Price per Ordinary Share for warrant holders)
Key Players & Entities
- Entera Bio Ltd. (company) — Registrant
- July 31, 2024 (date) — Earliest event date
- December 20, 2024 (date) — Filing date
- $5.85 (dollar_amount) — Warrant exercise price
FAQ
What specific matters were submitted to a vote of security holders that necessitated this amendment?
The filing does not specify the exact matters submitted to a vote, but it is an amendment to a report concerning such submissions.
What is the total number of warrants outstanding that are detailed in this filing?
The filing mentions warrants exercisable for half an Ordinary Share but does not specify the total number of warrants outstanding.
What is the expiration date of these warrants?
The expiration date of the warrants is not mentioned in this excerpt of the filing.
What is the rationale behind filing an amendment (8-K/A) rather than a new 8-K?
An 8-K/A is filed to amend or supplement a previously filed Current Report on Form 8-K, indicating a correction or addition to existing information.
Does this amendment affect the previously reported financial statements?
This amendment pertains to matters submitted to a vote and warrant details, not financial statements, so it is unlikely to directly affect them unless related to a vote on financial matters.
Filing Stats: 636 words · 3 min read · ~2 pages · Grade level 13.1 · Accepted 2024-12-20 16:05:26
Filing Documents
- zk2432475.htm (8-K/A) — 32KB
- 0001178913-24-004020.txt ( ) — 207KB
- entx-20240731.xsd (EX-101.SCH) — 5KB
- entx-20240731_def.xml (EX-101.DEF) — 18KB
- entx-20240731_lab.xml (EX-101.LAB) — 27KB
- entx-20240731_pre.xml (EX-101.PRE) — 20KB
- zk2432475_htm.xml (XML) — 7KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders Say-On-Frequency Determination As previously reported, at the Annual Meeting of Shareholders of the Company held on July 31, 2024 (the " Annual Meeting "), the Company's shareholders voted on, among other matters, a non-binding advisory vote regarding the frequency of future stockholder non-binding advisory votes on the compensation of the Company's named executive officers. The frequency of one year received the highest number of votes cast by shareholders at the Annual Meeting. Based on these advisory vote results, the Board has determined that the Company will hold a shareholder non-binding advisory vote on executive compensation every year until the Board otherwise determines that a different frequency for such non-binding, advisory votes is in the best interest of the Company or until the next required vote on the frequency of such votes .
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENTERA BIO LTD. Date: December 20, 2024 By: /s/ Miranda Toledano Name: Miranda Toledano Title: Chief Executive Officer